

# Press Release



## IgG/IgM Antibody-test Kit for COVID-19 launched in Japan

---

OSAKA, Japan, June, 3, 2020 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D. ; hereafter "Shionogi") today announced that Shionogi launched IgG/IgM Antibody-test Kit for COVID-19 as a research reagent in Japan.

Shionogi had entered into an agreement with Micro Blood Science Inc., the licensor of the kit. We have been working to collect clinical data for the purpose of confirming the usefulness of the kit for its practical use in Japan, as well as examining its indications and use methods. After evaluating the result of the test in cooperation with medical institutions, the test kit was not used as a diagnostic test for COVID-19 or as a Pre-PCR screening test, but was considered useful for epidemiological surveillance and studies of SARS-CoV-2/COVID-19 aiming to determine the number of individuals previously infected with SARS-CoV-2.

Shionogi is committed to "Protect people worldwide from the threat of infectious diseases" as our key focus. We are not limiting ourselves to the research and development of therapeutic medications, but are also focused on the total care of infectious disease through awareness building, prevention and diagnosis and suppression of exacerbation. To contribute the restoration of social security and safety through the early end of the pandemic, Shionogi will provide this test kit to medical insutitute,testing facilities, resarch laboratories, and local authorities, companies, and so on the premise that it will be used under the judgement of physicians.

### Forward-Looking Statements

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcomes of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

### For Further Information, Contact:

Corporate Communications Department  
Shionogi & Co., Ltd.  
Telephone: +81-6-6209-7885